ADAR1 调控巨噬细胞外泌体改善脓毒性心肌病心肌损伤的治疗潜力
核心信息
- 论文英文标题: Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy
- 期刊: J Nanobiotechnology
- 发表年份: 2026
- DOI: 10.1186/s12951-026-04368-4
- PMID/PMCID: 41965774; PMC13200382
研究概览
Our study reveals a novel ADAR1-miR-122-XIAP axis in macrophage exosomes that protects against sepsis-induced myocardial injury, offering a potential disease modulation strategy for SICM. The molecular mechanisms that underlie SICM remain elusive, and effective therapies are limited.
核心发现
Here, we report a pivotal role for adenosine deaminases acting on RNA-1 (ADAR1) in modulating macrophage polarization and exosome-mediated intercellular communication, which ameliorates myocardial damage in SICM.
We determined that ADAR1 overexpression in macrophages promotes an anti-inflammatory M2 phenotype, reduces myocardial inflammation, and inhibits cardiomyocyte apoptosis in a murine model of sepsis.
Mechanistically, ADAR1 regulates the level of microRNA-122 (miR-122) in macrophage-derived exosomes.
Exosomal miR-122 targets X-linked inhibitor of apoptosis protein (XIAP), modulating cardiomyocyte survival.
Echo Biotech 角色
ExoLoad核酸负载试剂盒
关联平台: Echosome®, Research Reagents & Tools
关联服务与能力: Small RNA / Cargo Loading, Research Reagent / Product Supply
关联产品或试剂: ExoLoad® Nucleic Acid Loading Kit
参考文献
原始论文: Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy Journal of nanobiotechnology. 2026. DOI: 10.1186/s12951-026-04368-4. PMID/PMCID: 41965774; PMC13200382.